Print this page    •   Back to Web version of article

The Body Covers: The 12th International AIDS Conference

Session 286/12204: Combination Abacavir (1592, ABC)/Amprenavir (141W94) Therapy in HIV-1 Infected Antiretroviral Naïve Subjects with CD4+ Cell Counts >400 cells/mL and Viral Load >5000 copies/mL

Coverage provided by Michael Giordano, M.D.

June 29, 1998

Dr. Bart and colleagues presented preliminary results from this open-label study of abacavir, an experimental nucleoside analog reverse transcriptase inhibitor, and amprenavir, an experimental protease inhibitor, in 40 treatment-naïve patients.

Interim Week 24 results from this 72-week study were presented. Twenty-eight patients had reached Week 24 at the time of the analysis. Twenty-five of them, or 89%, had undetectable levels of HIV (<500 copies/mL). Thirty-eight patients had reached Week 8, and all but one of them (97%) had viral load levels below the limit of detection.

There are concerns about the side effects of these drugs, especially one known as a 'hypersensitivity reaction' (HR) that has been seen in 3% of patients enrolled on abacavir studies. The symptoms of HR include fever and nausea, malaise, and most significantly, a rash that can be life-threatening. These symptoms can appear within several days to six weeks after starting abacavir, and go away after abacavir is stopped. However, abacavir must never be started again after such a reaction -- one patient on an abacavir study has died after re-starting therapy.

This article was provided by Copyright Body Health Resources Corporation. All rights reserved.

You can find this article online by typing the following address into your Web browser:

Please Note: Knowledge about HIV changes rapidly. Note the date of this article's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this article.

General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your healthcare provider.